Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.

Oncotarget · 2016 · PMC5347689 · PMID 27756884

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the ACT treatment effect in stage I patients did not reach statistical significance, stage I patients with high E2F, 5-year survival increased from 31% without ACT to 61% with ACT.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.